Valuation: 4D Molecular Therapeutics, Inc.

Market Cap 661M 593M 548M 496M 927M 62.93B 939M 6.55B 2.61B 32.93B 2.48B 2.43B 105B P/E 2026 *
-2.89x
P/E 2027 * -2.99x
Enterprise Value 466M 418M 386M 350M 653M 44.34B 661M 4.62B 1.84B 23.2B 1.75B 1.71B 73.66B EV / Sales 2026 *
35.1x
EV / Sales 2027 * 15.8x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: 4D Molecular Therapeutics, Inc.

1 day+3.89%
1 week-0.08%
Current month-11.88%
1 month-13.39%
3 months+28.02%
6 months+33.86%
Current year+68.13%
1 week 10.62
Extreme 10.62
13.12
1 month 10.62
Extreme 10.62
14.97
Current year 6.96
Extreme 6.96
16.93
1 year 6.96
Extreme 6.96
16.93
3 years 2.24
Extreme 2.235
36.25
5 years 2.24
Extreme 2.235
36.25
10 years 2.24
Extreme 2.235
55.11
Manager TitleAgeSince
Chief Operating Officer 51 31/03/2018
Chief Executive Officer 64 11/09/2013
Director of Finance/CFO 51 16/11/2025
Director TitleAgeSince
Chairman 64 11/09/2013
Director/Board Member 62 30/11/2015
Director/Board Member 47 28/02/2019
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Founder

-58,333 0.1056%
16/09/26 Exercice

Compliance Officer

4,905 0.0089%
14/09/26 Sell

Founder

-58,333 0.1056%
Change 5-day change 1-year change 3-year change Capi.($)
+3.85%-0.08%+5.35%+18.63% 661M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.07%+0.16%+27.02%+56.40% 44.75B
+2.32%-3.16%+18.12%+100.56% 41.62B
+0.18%-3.59%+222.01%+920.79% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.33%-1.25%+47.14%+147.80% 38.11B
Weighted average by Cap. +3.06%-0.30%+47.15%+160.58%

Financials

2026 *2027 *
Net sales 13.26M 11.89M 11M 9.96M 18.61M 1.26B 18.83M 131M 52.37M 661M 49.74M 48.69M 2.1B 20.63M 18.51M 17.12M 15.5M 28.96M 1.97B 29.31M 205M 81.51M 1.03B 77.43M 75.79M 3.26B
Net income -289M -259M -239M -217M -405M -27.49B -410M -2.86B -1.14B -14.38B -1.08B -1.06B -45.66B -316M -284M -262M -238M -444M -30.12B -449M -3.14B -1.25B -15.76B -1.19B -1.16B -50.03B
Net Debt -195M -175M -162M -147M -274M -18.59B -277M -1.94B -771M -9.73B -732M -717M -30.88B -334M -300M -277M -251M -469M -31.82B -475M -3.31B -1.32B -16.65B -1.25B -1.23B -52.86B
Projected Income Statement - Annual - 4D Molecular Therapeutics, Inc.
Logo 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Employees
196
Date Price Change Volume
28/10/26 US$12.63 +5.60% 450,994
27/10/26 US$11.96 +8.43% 1,134,654
26/10/26 US$11.03 +2.13% 1,084,578
23/10/26 US$10.80 -8.86% 996,140
22/10/26 US$11.85 -6.10% 1,354,686
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - 4D Molecular Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
11.96USD
Average target price
28.09USD
Spread / Average Target
+134.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - 4D Molecular Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FDMT Stock